Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.847 USD | +5.07% | +15.95% | +4.93% |
Apr. 25 | Transcript : HOOKIPA Pharma Inc. - Special Call | |
Apr. 25 | HOOKIPA Pharma Inc. Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.93% | 79.76M | |
+26.23% | 653B | |
+27.00% | 556B | |
-6.51% | 354B | |
+20.47% | 331B | |
+3.74% | 296B | |
+13.36% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.35% | 144B |
- Stock Market
- Equities
- HOOK Stock
- News HOOKIPA Pharma Inc.
- Hookipa Pharma : Merck Collaborate on Head, Neck Cancer Combo Therapy Development